Last reviewed · How we verify
NCT05624216
Radiofrequency and Targeted Pressure Energy for Cellulite Reduction
NA trial testing BTL-084 in Cellulite in 28 participants. Completed in 25 October 2021.
8 April 2020
Quick facts
| Lead sponsor | BTL Industries Ltd. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 28 |
| Start date | 30 July 2019 |
| Primary completion | 8 April 2020 |
| Estimated completion | 25 October 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- BTL-084
Conditions studied
- Cellulite — all drugs for Cellulite →
- Cellulitis — all drugs for Cellulitis →
- Cellulitis of Leg — all drugs for Cellulitis of Leg →
Sponsor
BTL Industries Ltd. — full company profile →
Who can join
21 and older, any sex, with Cellulite or Cellulitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the clinical efficacy and safety of radiofrequency heating and targeted pressure energy for reduction in the appearance or cellulite. The study is a prospective multi-center open-label single-arm study. Subjects will be required to complete four (4) treatment visits and two to three follow-up visits - 1, 3 and 6 months after the last therapy visit. All of the study subjects will receive the treatment with the subject device.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Combined Monopolar Radiofrequency and Targeted Pressure Energy for the Treatment and Improvement of Cellulite Appearance on Multiple Body Parts.
Busso M, Born T. · · 2023 · PMID 37288281
Verify or expand the search:
- PubMed search for NCT05624216
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cellulite
Currently open trials in the same condition.
- NCT06791564 — Minimally Invasive Active Release of Septa Bands for Cellulite and Connective Tissue Release for Fibrosis Treatment in B · NA · recruiting
Other BTL Industries Ltd. trials
Trials by the same sponsor.
- NCT07413692 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and E · NA · recruiting
- NCT07413705 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and · NA · recruiting
- NCT07179224 — EEG Changes After rTMS Stimulation · NA · completed
- NCT07024550 — Impact of the EXOMIND (BTL-699-2) on the Brain Reward Pathway · NA · active not recruiting
- NCT07027657 — EXOMIND (BTL-699-2) for the Improvement of Sleep Quality and Reduction of Stress · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05624216 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BTL Industries Ltd.
- Last refreshed: 22 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05624216.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing